The ECJ’s Illumina/Grail judgment has curtailed the Commission’s direct oversight of certain transactions, thereby elevating the need for national "call-in" powers. These call-in regimes, which are proliferating both inside...more
In the much-anticipated Lundbeck case (i.a. C-591/16 P), the European Court of Justice (“ECJ”) on 25th March 2021 confirmed the decision of the European Commission (“Commission”) to impose fines on Lundbeck and several...more
4/21/2021
/ Anti-Competitive ,
Antitrust Provisions ,
Competition ,
Drug Distribution ,
Duty of Care ,
European Commission ,
European Court of Justice (ECJ) ,
Generic Drugs ,
Life Sciences ,
Pay-For-Delay ,
Pharmaceutical Industry